Compare American Electric Power Company Inc (AEP) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
American Electric Power Company Inc vs Recursion Pharmaceuticals Inc — how do they compare? American Electric Power Company Inc trades at $136.43 (market cap $74.83B), while Recursion Pharmaceuticals Inc trades at $3.71 (market cap $2.04B). The key difference: American Electric Power Company Inc is far larger — about 36.7× Recursion Pharmaceuticals Inc's market cap, and American Electric Power Company Inc pays a 2.76% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AEP | RXRX | |
|---|---|---|
Market Cap | $74.83B | $2.04B |
Sector | Utilities | Health |
52-Week High | $138.69 | $6.79 |
52-Week Low | $103.96 | $2.84 |
Enterprise Value | $126.09B | $1.46B |
Dividend Yield | 2.76% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AEP trades at $137.53, down 0.71% on the day, with strong analyst support (64% buy ratings) and a $142.82 consensus price target. The stock shows bullish technical momentum with recent earnings beats and robust revenue growth, climbing from $19.7B in 2024 to $21.9B in 2025. AEP benefits from AI-driven electricity demand and a $78B capital plan for grid expansion.
Outlook remains positive given AEP's strategic positioning in energy infrastructure, though risks include high capital expenditures and debt levels. The current valuation at 20.12x P/E appears reasonable for a utility with stable earnings growth and dividend payments, supporting a constructive view for long-term investors.
RXRX trades at $3.96, up 4.21% today, with a bullish technical signal from moving averages despite overbought RSI readings. The company shows improving quarterly EPS beats but faces deep losses with a -851.51% net margin. Recent news highlights its AI-driven drug discovery platform and inclusion in Cathie Wood's portfolio (The Motley Fool, 2026-07-05).
Analyst consensus is mixed with 40% buy ratings and a $7.83 price target suggesting significant upside, but high cash burn and negative profitability pose substantial risks. Investment appeal hinges on successful clinical advancements offsetting current financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About American Electric Power Company Inc
American Electric Power is one of the largest regulated utilities in the United States, providing electricity generation, transmission, and distribution to more than 5 million customers in 11 states. About 43% of AEP's of capacity is coal, with the remainder from a mix of natural gas (27%), renewable energy and hydro (19%), nuclear (7%), and demand response (4%). Vertically integrated utilities, transmission and distribution, and generation and marketing support earnings.
Read more on AEP →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
